The yield of genetic workup for middle-aged and elderly patients with neurological disorders in a real-world setting.

Diagnostic yield Exome sequencing Genetic testing Neurogenetics Neurological disorders Older population

Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
31 May 2024
Historique:
received: 07 11 2023
revised: 25 04 2024
accepted: 29 05 2024
medline: 6 7 2024
pubmed: 6 7 2024
entrez: 5 7 2024
Statut: aheadofprint

Résumé

Genetic workup is becoming increasingly common in the clinical assessment of neurological disorders. We evaluated its yield among middle-aged and elderly neurological patients, in a real-world context. This retrospective study included 368 consecutive Israeli patients aged 50 years and older (202 [54.9%] males), who were referred to a single neurogenetics clinic between 2017 and mid-2023. All had neurological disorders, without a previous molecular diagnosis. Demographic, clinical and genetic data were collected from medical records. The mean age at first genetic counseling at the clinic was 62.3 ± 7.8 years (range 50-85 years), and the main indications for referral were neuromuscular, movement and cerebrovascular disorders, as well as cognitive impairment and dementia. Out of the 368 patients, 245 (66.6%) underwent genetic testing that included exome sequencing (ES), analysis of nucleotide repeat expansions, detection of specific mutations, targeted gene panel sequencing or chromosomal microarray analysis. Overall, 80 patients (21.7%) received a molecular diagnosis due to 36 conditions, accounting for 32.7% of the patients who performed genetic testing. The diagnostic rates were highest for neuromuscular (58/186 patients [31.2%] in this group, 39.2% of 148 tested individuals) and movement disorders (14/79 [17.7%] patients, 29.2% of 48 tested), but lower for other disorders. Testing of nucleotide repeat expansions and ES provided a diagnosis to 28/73 (38.4%) and 19/132 (14.4%) individuals, respectively. Based on our findings, genetic workup and testing are useful in the diagnostic process of neurological patients aged ≥50 years, in particular for those with neuromuscular and movement disorders.

Identifiants

pubmed: 38968664
pii: S0022-510X(24)00209-0
doi: 10.1016/j.jns.2024.123074
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123074

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no financial interests that are directly or indirectly related to the work submitted for publication.

Auteurs

Noga Lempel (N)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Shahar Shelly (S)

Department of Neurology, Rambam Medical Center, Haifa, Israel; Rappaport Faculty of Medicine, Technion, Haifa, Israel; Department of Neurology, Mayo Clinic, Rochester, MN, United States of America.

Odelia Chorin (O)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Rachel Rock (R)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Aviva Eliyahu (A)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Yael Finezilber (Y)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Hana Poran (H)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Neta Feinstein-Goren (N)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Meirav Segev (M)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Haike Reznik-Wolf (H)

The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Ortal Barel (O)

The Genomics Unit, Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel.

David Orion (D)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.

Saar Anis (S)

Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel; Movement Disorders Institute, Sheba Medical Center, Tel Hashomer, Israel.

Miriam Regev (M)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Hagith Yonath (H)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel; Department of Internal Medicine A, Sheba Medical Center, Tel Hashomer, Israel.

Dan Dominissini (D)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Genomics Unit, Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel; The Wohl Institute for Translational Medicine, Sheba Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel.

Ilan Blatt (I)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Sharon Hassin-Baer (S)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel; Movement Disorders Institute, Sheba Medical Center, Tel Hashomer, Israel.

Amir Dori (A)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Neurology, Sheba Medical Center, Tel Hashomer, Israel.

Elon Pras (E)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel.

Lior Greenbaum (L)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel; The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel. Electronic address: lior.greenbaum@sheba.health.gov.il.

Classifications MeSH